高压氧预处理对宫内缺血缺氧大鼠脑组织及血浆神经肽Y含量的影响

目的 :探讨高压氧 (HBO)预处理对宫内缺血缺氧大鼠脑组织及血浆神经肽Y含量的影响。方法 :采用放射免疫法测定 2 5例正常胎鼠 (对照组 )、2 7例宫内缺血缺氧胎鼠 (缺血缺氧组 )及 1 9例经高压氧预处理宫内缺血缺氧胎鼠 (HBO组 )中枢及外周血神经肽Y的含量。结果 :HBO组胎鼠脑及外周血神经肽Y的含量分别为 52 .64±1 2 .1 6pg/mg及 1 99.51± 49.36ng/L ,缺血缺氧组胎鼠脑及外周血神经肽Y的含量分别为87.2 5± 2 3.63pg/mg及 2 51 .53±55 .2 8ng/L ,对照组胎鼠神经肽Y含量为 48.63± 1 0 .72pg/mg及 1 4 7.35± 31 .49ng/L ;与对照组相比 ,缺血缺氧组胎鼠中枢及外周神经肽Y含量均显著升高 (P <0 .0 1 ) ;HBO组神经肽Y含量显著低于缺血缺氧组 (P <0 .0 5)。结论 :神经肽Y与围生期缺血缺氧的发生密切相关 ,HBO预处理具有改善宫内缺血缺氧的作用 ,其机理可能与抑制神经肽Y的生成有关     

卡托普利对心脏成纤维细胞端粒长度的作用研究

目的探讨卡托普利对心脏成纤维细胞端粒长度的影响。方法使用流式荧光原位杂交法（Flow—Fish）检测成纤维细胞端粒长度的变化。结果经过卡托普利处理过的成纤维细胞端粒明显缩短。结论本研究通过Flow—Fish法证实了卡托普利能缩短成纤维细胞端粒的长度，引起心脏成纤维细胞衰老的发生，从而抑制CFs的增殖。     

走罐配合耳穴贴压治疗痤疮40例

痤疮俗称"粉刺",好发于颜面及胸背部等处,患者多为青年,影响容貌,易反复发作.笔者自2000年以来,采用背部膀胱经走罐配合王不留行籽耳穴贴压治疗痤疮40例,取得满意疗效,现报道如下.     

Smad4和Smad7在人脑胶质瘤中的表达及意义

目的探讨Smad4和Smad7在人脑胶质瘤中的表达及意义.方法采用免疫组化方法,对临床经过石蜡包埋的30例胶质瘤和8例正常脑组织标本进行定位和定性检测.结果 Smad4 和 Smad7蛋白在胶质瘤中有不同程度的表达,在正常脑组织、低、高级别胶质瘤中Smad4的阳性表达分别为44.80±16.19,25.81±9.48,6.73±3.71,P<0.05.Smad7的阳性表达分别为6.69±3.86,18.22±7.84,41.95±17.27,P<0.05.差别均有显著意义.且Smad4与Smad7的表达水平呈负相关,r＝-0.82,P<0.01.结论 Smad4随胶质瘤的病理分级增高阳性表达降低,对胶质瘤的进展有抑制作用.Smad7则相反,可能参与了胶质瘤的恶性进展.     

异甘草素对人前列腺癌细胞体外增殖的抑制作用

目的:观察异甘草素(ISL)对人前列腺癌细胞体外增殖的抑制作用。方法:采用MTT法测定细胞增殖。结果:ISL浓度依赖性(0~20μm)抑制人前列腺癌细胞增殖,IC50为12.58μm,且呈时间依赖性,ISL20μm作用3天时的抑制率为85.26%。结论:异甘草素能有效地抑制前列腺癌细胞的增生,异甘草素有可能成为一种治疗前列腺癌的新药。     

Louki Zupa decoction attenuates the airway inflammation in acute asthma mice induced by ovalbumin through IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway

ContextAsthma is a common respiratory system disease. Louki Zupa decoction (LKZP), a traditional Chinese medicine, presents a promising efficacy against lung diseases.ObjectiveTo investigate the pathogenic mechanism of asthma and reveal the intervention mechanism of LKZP.Materials and methodsForty-eight female Balb/c mice were randomly divided into 6 groups: normal control group (NC), ovalbumin (OVA)/saline asthma model group, OVA/LL group, OVA/LM group, OVA/LH group and OVA/DEX group (n = 8 per group). The asthmatic mice were modelled through intraperitoneal injecting and neutralizing OVA. LKZP decoction was administrated by gavage at the challenge stage for seven consecutive days (2.1, 4.2 and 8.4 g/kg/day). We investigated the change in lung function, airway inflammation, mucus secretion and TH-1/TH-2-related cytokines. We further verify the activated status of the IL-33/ST2/NF-κB/GSK3β/mTOR signalling pathway.ResultsLKZP was proved to improve asthmatic symptoms, as evidenced by the down-regulated airway resistance by 36%, 58% and 53% (p < 0.01, p < 0.001 vs. OVA/saline group), up-regulated lung compliance by 102%, 114% and 111%, decreased airway inflammation and mucus secretion by 33%, 40% and 33% (p < 0.001 vs. OVA/saline group). Moreover, the content of cytokines in BALF related to airway allergy (such as IgE) and T helper 1/T helper 2 cells (like IL-2, IL-4, IL-5, IL-13, TNF-α and IFN-γ), were also markedly reduced by 13–65% on LKZP intervention groups compared with model group. Mechanistic research revealed that the IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway was activated in the OVA/saline group and LKZP significantly down-regulated this pathway.Discussion and conclusionLKZP improves lung function, airway inflammation, mucus secretion and correct immune imbalance by intervening with the IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway, presenting a promising therapeutic choice for asthma.     

向日葵胰蛋白酶抑制剂SFTI的合成及酶抑制动力学研究

目的 考察合成的向日葵胰蛋白酶抑制剂的抑制效果,计算其抑制常数Ki.方法 采用Fmoc固相化学合成方法,反相柱纯化后用CytofluorTM微孔板发光检测仪测定向日葵胰蛋白酶抑制剂的抑制常数.结果与结论 向日葵胰蛋白酶抑制剂的Ki值为2.2nM±0.5(n=8),抑制效果良好.     

Triple Therapy-Based on Tegoprazan,a New Potassium-Competitive Acid Blocker,for First-Line Treatment of Helicobacter pylori Infection: A Randomized,Double-Blind,Phase III,Clinical Trial

Background/AimsWe examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.MethodsA randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.ResultsIn total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.ConclusionsTPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier {"type":"clinical-trial","attrs":{"text":"NCT03317223","term_id":"NCT03317223"}}NCT03317223).     

Recovery of complete left bundle branch block in a dilated cardiomyopathy patient after treatment with sacubitril/valsartan: A case report

Rationale:The treatment of dilated cardiomyopathy (DCM) has recently been greatly improved, especially with the widespread use of sacubitril/valsartan (ARNI) combination therapy. We know that ARNI-like drugs can significantly improve the symptoms of heart failure with reducing ejection fraction. However, clinical studies evaluating the safety and efficacy of ARNI in DCM-associated arrhythmia are limited, and whether individuals with arrhythmia would benefit from ARNI remains controversial. In this case, we report a patient with complete left bundle branch block (CLBBB) associated with DCM whose CLBBB returned to normal after treatment with ARNI.Patient concerns:A 38-year-old man was admitted to the hospital for 20 days for idiopathic paroxysmal dyspnea. He presented with exacerbated dyspnea symptoms at night, accompanied by cough and sputum.Diagnosis:Physical examination revealed a grade 4/6 systolic murmur could be heard in the apical area of the heart and mild edema was present in both lower limbs. Laboratory examination found that the B-type natriuretic peptide was significantly increased. Echocardiography indicated left atrial internal diameter, right ventricular internal diameter, and left ventricular diastolic diameter were enlarged and ejection fraction was significantly decreased. Besides, the pulsation of the wall was diffusely attenuated. Electrocardiogram was suggestive of tachycardia and CLBBB. A diagnosis of DCM with CLBBB was considered based on a comprehensive evaluation of the physical examination, laboratory examination, echocardiography and electrocardiogram.Interventions:The patient was treated with ARNI at a dose of 50 mg (twice a day) at first, gradually increasing to the target dose (200 mg, twice a day) in the following 9 months as shown in Table ​Table1,1, along with metoprolol 25 mg (once a day [qd]), diuretics 20 mg (qd), and aldosterone 20 mg (qd).Table 1Specific medications used in treatment.

丙泊酚用于精神病患者人工通气镇静治疗的临床效果评价

目的研究丙泊酚对精神病患者人工通气在治疗慢性阻塞性肺疾病（COPD）伴重度高碳酸性呼吸衰竭的镇静效果。方法将44例COPD伴重度高碳酸性呼吸衰竭的精神病患者按入院顺序完全随机分为2组各22例,对照组：咪唑安定静脉注射10—20mg;丙泊酚组：丙泊酚静脉注射泵持续输注0．5～2．0mg/（kg·h）,比较治疗0．5、1h后,2组动脉血气分析中的pH值、氧分压（PaO2）、二氧化碳分压（PaCO2）变化,峰值气道压力（Pmax）、平台压（Ppalt）以及肺功能中第1秒用力呼气量与用力肺活量的比值（FEV1／FVC）和呼气峰流速（PEF）的变化。结果丙泊酚组的镇静效果显著优于对照组;与对照组比较,丙泊酚组在治疗后PaCO2显著降低,pH值在治疗后0．5h回到正常范围内,恢复较迅速（P〈0．05或P〈0．01）;治疗后0．5h的PaO2、PaO2／FiO2也比对照组明显升高。丙泊酚组在治疗后的Pmax、Ppalt较对照组有明显下降,PEF、FEV1／FVC的提高较对照组显著,差异有统计学意义（P〈0．05或P〈0．01）。结论丙泊酚进行镇静在COPD伴重度高碳酸性呼吸衰竭治疗中可降低气道阻力,改善氧合功能,减少精神病患者的人机对抗。